Health Care Sector News

Latest News

  • An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain's GW Pharmaceuticals to a record high on Monday. GW, which was founded in 1998 to capitalise on the medical benefits of cannabis, said it now expected to submit a …

  • Should you avoid Shire plc (LON: SHP) in favour of this healthcare peer?

  • French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, ...

  • Shire raises eyebrows with stunning debut Reuters - UK Focus - Fri, Sep 23, 2016 20:03 BST

    Investors piled into the debut bond from Shire (Xetra: S7E.DE - news) this week, ignoring some clear warning signals that the drugmaker's deal might have offered a little bit less than meets the eye. The US$12.1bn trade amassed a US$28.5bn order book, even as analysts were noting that Shire's debt-to-Ebitda ratio had …

  • European shares retreat after Fed-inspired rally; Lundbeck slumps Reuters - UK Focus - Fri, Sep 23, 2016 17:25 BST

    European shares ended weaker on Friday, pulling back from two-week highs in the previous session after the Federal Reserve signalled an increasingly cautious approach to future rate hikes, with banks leading ...

  • Air Liquide bonds outperform in softer market Reuters - UK Focus - Fri, Sep 23, 2016 17:02 BST

    Spreads on Air Liquide Finance's bonds that were part of the French gas company's dollar bond debut were tighter on Friday, a day after pricing, despite a weaker market tone. Air Liquide (LSE: 0NWF.L - news) 's 30-year bonds were being quoted at Treasuries plus 105bp, or 13bp inside their pricing levels, while the 10-year …

  • Will this healthcare stock keep beating AstraZeneca plc (LON: AZN)?

  • European shares pull back after Fed-inspired rally; RWE falls Reuters - UK Focus - Fri, Sep 23, 2016 10:28 BST

    European shares fell on Friday, pulling back from two-week highs hit the previous session after the Federal Reserve signalled an increasingly cautious approach to future rate hikes, with banks leading ...

  • European shares pull back after Fed-inspired rally; Lundbeck slumps Reuters - UK Focus - Fri, Sep 23, 2016 08:18 BST

    European shares fell in early trading on Friday, pulling back from two-week highs hit in the previous session following the U.S. Federal Reserve's decision to push back on its next rate increase. By 0708 ...

  • Will GlaxoSmithKline plc's (LON: GSK) new CEO be a blessing or a curse for shareholders?

  • High margin businesses and huge markets mean these two FTSE 100 (INDEXFTSE: UKX) giants could be great for growth investors.

  • Are these top healthcare stocks in your portfolio? Fool.co.uk - Wed, Sep 21, 2016 15:26 BST

    These two healthcare stocks are attractive on long-term fundamentals.

  • Is Sinclair Pharma plc a better bet than GlaxoSmithKline plc? Fool.co.uk - Wed, Sep 21, 2016 12:32 BST

    Does Sinclair Pharma plc (LON: SPH) have the growth potential to bring you more riches than GlaxoSmithKline plc (LON: GSK)?

  • AstraZeneca pulls cancer drug application in Europe Reuters - UK Focus - Wed, Sep 21, 2016 11:21 BST

    AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised ...

  • Breaking the mould: GSK picks Big Pharma's first female CEO Reuters - UK Focus - Tue, Sep 20, 2016 15:46 BST

    Emma Walmsley, GlaxoSmithKline (Other OTC: GLAXF - news) 's incoming CEO, breaks the mould as the first woman to lead a top global drugmaker and stands out among Big Pharma bosses as a consumer brands guru rather than a prescription medicines expert. "GSK will get applause for appointing a woman to a position no woman …

  • Is Shield Therapeutics plc a better bet than AstraZeneca plc? Fool.co.uk - Tue, Sep 20, 2016 15:27 BST

    Does the small-cap potential of Shield Therapeutics plc (LON: STX) beat the blue chip reliability of AstraZeneca plc (LON: AZN) in the pharma stakes?

  • Should you buy GlaxoSmithKline plc after its change in CEO? Fool.co.uk - Tue, Sep 20, 2016 11:43 BST

    Is GlaxoSmithKline plc (LON: GSK) more or less appealing after a change in senior management?

  • GlaxoSmithKline names insider Emma Walmsley as new CEO Reuters - UK Focus - Tue, Sep 20, 2016 11:01 BST

    GlaxoSmithKline (Other OTC: GLAXF - news) said on Tuesday it had chosen its head of consumer healthcare, Emma Walmsley, as its new chief executive, after several months reviewing internal and external candidates. Walmsley, 47, joined Britain's biggest drugmaker in 2010 from L'Oreal and will replace Andrew Witty, who had …

  • Wage talks between South Africa's Amplats, union hit deadlock Reuters - UK Focus - Tue, Sep 20, 2016 10:43 BST

    A South African union declared a wage dispute with the world's top platinum producer and a unit of Anglo American (LSE: AAL.L - news) on Tuesday after negotiations deadlocked, setting the stage for a potential strike. The National Union of Mineworkers (NUM) said in a statement it had rejected the latest offer of a 6.75 …

  • South Africa's NUM union declares wage dispute with Amplats Reuters - UK Focus - Tue, Sep 20, 2016 10:06 BST

    South Africa's National Union of Mineworkers declared a wage dispute with Anglo American Platinum on Tuesday after negotiations deadlocked, setting the stage for a potential strike. The union said in a ...

  • GlaxoSmithKline names consumer head Walmsley new CEO Reuters - UK Focus - Tue, Sep 20, 2016 07:13 BST

    GlaxoSmithKline said on Tuesday it had chosen Emma Walmsley, head of consumer healthcare, as its new chief executive, after considering internal and external candidates. Walmsley, who joined Britain's ...

  • HIGHGRADE CLOSE-Five high-grade issuers raise US$15.614bn Reuters - UK Focus - Mon, Sep 19, 2016 22:39 BST

    * Biggest third quarter on record * Third consecutive US$300bn plus quarter * Shire over 2 times covered * St Joseph Health upsized to US$700m * Most actively traded: GILD 4.15% 2047s * Monthly issuance: ...

  • Shire launches US$12.1bn four-part deal: Lead Reuters - UK Focus - Mon, Sep 19, 2016 19:58 BST

    By Mike Gambale and Hillary Flynn NEW YORK, Sept 19 - Here is the pricing progression on the new bond offering from drugmaker Shire to help finance its acquisition of Baxalta, one of the banks leading ...

  • Shire selling long-awaited M&A bond Reuters - UK Focus - Mon, Sep 19, 2016 16:29 BST

    By Hillary Flynn NEW YORK, Sept 19 - Drugmaker Shire is selling a four-tranche M&A bond on Monday to help finance its acquisition of Baxalta, a long anticipated trade that is expected to be up to US$12bn ...

  • Order book for Shire's M&A bond reach US$25bn: lead Reuters - UK Focus - Mon, Sep 19, 2016 16:28 BST

    By Hillary Flynn NEW YORK, Sept 19 - The order book for drugmaker Shire's M&A bond have reached US$25bn, one of the banks managing the deal told IFR. The deal, expected to be up to US$12bn in size, is ...

  • Shire selling four tranche US dollar bond for Baxalta buy :lead Reuters - UK Focus - Mon, Sep 19, 2016 13:36 BST

    By Mike Gambale NEW YORK, Sept 19 - Here is the pricing progression on the new bond offering from drugmaker Shire to help finance its acquisition of Baxalta, one of the banks leading the deal told IFR. ...

  • GSK cuts vaccine price for refugees, bowing to pressure Reuters - UK Focus - Mon, Sep 19, 2016 12:34 BST

    GlaxoSmithKline (Other OTC: GLAXF - news) is cutting the price charged for its pneumococcal vaccine when given to refugees, following complaints about the product's "exorbitant" cost by medical charity Medecins Sans Frontieres. GSK said its offer was made on the basis that others would not seek to reference the special …

  • Shire readies up to US$12bn M&A bond Reuters - UK Focus - Fri, Sep 16, 2016 18:35 BST

    Drugmaker Shire (Baa3/BBB-) is readying an up to US$12bn M&A bond, the next test for the corporate bond market that has proved resilient in the wake of volatility. A bond sale of this size should be well received in what remains an active primary market in the US, where US$93.32bn of the US$130bn syndicate desks were forecasting …

  • Britain's FTSE falls as banking stocks lose ground Reuters - UK Focus - Fri, Sep 16, 2016 17:35 BST

    Britain's top share index fell on Friday to record a second straight week of losses as heavyweight bank stocks dropped after U.S. regulators demanded $14 billion from Deutsche Bank to settle claims over ...

  • How a new train station could expand Cambridge's 'red-hot' property market

  • Investors still hooked on US corporate bonds Reuters - UK Focus - Fri, Sep 16, 2016 15:02 BST

    After a cautious start, the primary market swung back into action with almost US$40bn in 54 bond tranches sold this week by names like biotech company Gilead Sciences (NasdaqGS: GILD - news) , tech giant Cisco Systems and Deutsche Telekom (LSE: 0MPH.L - news) .

  • MPs launch probe into executive pay and corporate governance

    MPs are to investigate soaring executive pay as part of a wide-ranging probe into the way UK companies are run and the laws that govern them. The announcement of the investigation into corporate governance - first revealed by Sky News - follows anger over working practices at Sports Direct and the collapse of BHS …

  • Astrazeneca says Forxiga combination beats use of drug alone Reuters - UK Focus - Fri, Sep 16, 2016 12:52 BST

    AstraZeneca said combining its Forxiga type-2 diabetes drug with older medicine Bydureon was more effective at controlling blood sugar levels than treatment with either drug on its own. In a late stage ...

  • AGM Statement Business Wire - Fri, Sep 16, 2016 12:47 BST

    LONDON--(BUSINESSWIRE)-- ECO Animal Health Group plc (“ECO” or the Company) Result of the Annual General Meeting At the Annual General Meeting of the Company held on 16 September 2016, all of the resolutions ...

  • GSK closes UK factory due to flooding Reuters - UK Focus - Fri, Sep 16, 2016 11:39 BST

    Britain's biggest drugmaker GlaxoSmithKline said it had been forced to shut a factory at Maidenhead west of London due to flooding, potentially causing disruption to the site which produces toothpaste ...

Next >>